Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2025)

Arcus Biosciences has reported Long-Term Investments over the past 9 years, most recently at $29.0 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $29.0 million for Q4 2025, up 107.14% from a year ago — trailing twelve months through Dec 2025 was $29.0 million (up 107.14% YoY), and the annual figure for FY2025 was $29.0 million, up 107.14%.
  • Long-Term Investments for Q4 2025 was $29.0 million at Arcus Biosciences, up from $10.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for RCUS hit a ceiling of $218.7 million in Q3 2021 and a floor of $2.0 million in Q3 2024.
  • Median Long-Term Investments over the past 5 years was $87.0 million (2021), compared with a mean of $84.5 million.
  • Biggest five-year swings in Long-Term Investments: soared 8001.11% in 2021 and later tumbled 98.68% in 2024.
  • Arcus Biosciences' Long-Term Investments stood at $182.0 million in 2021, then decreased by 29.12% to $129.0 million in 2022, then fell by 17.05% to $107.0 million in 2023, then crashed by 86.92% to $14.0 million in 2024, then soared by 107.14% to $29.0 million in 2025.
  • The last three reported values for Long-Term Investments were $29.0 million (Q4 2025), $10.0 million (Q3 2025), and $16.0 million (Q2 2025) per Business Quant data.